In the News

Switching to sulfonylureas from metformin monotherapy may increase risk of cardiovascular, hypoglycemic events

The results suggest that continuing metformin alone and accepting higher HbA1c targets may be preferable to switching to sulfonylureas when considering macrovascular outcomes and hypoglycemia, an accompanying editorial said.

Intermittent fasting appears effective for HbA1c reduction in type 2 diabetes

Patients on the intermittent energy restriction diet ate 500 to 600 kcal/d on two nonconsecutive days each week and followed their usual diet on the other days. They were compared to a group eating 1,200 to 1,500 kcal/d.

Preoperative glucose levels may predict postoperative cardiac outcomes regardless of whether patients have diabetes

For patients without diabetes, predictors of myocardial injury after noncardiac surgery included a casual glucose level of more than 6.86 mmol/L (124 mg/dL) and a fasting glucose level of more than 6.41 mmol/L (116 mg/dL).

MKSAP quiz: Hypoglycemia unawareness

This month's quiz asks readers to evaluate a 60-year-old man who is unable to detect hypoglycemia but is concerned about hyperglycemia and desires to reach an HbA1c level of less than 7%.

Spotlight on diabetic retinopathy

Recent studies looked at diabetic retinopathy's associations with age-related macular degeneration, chronic kidney disease, and different classes of diabetes drugs.

Bariatric surgery for type 2 diabetes associated with reduced risk of microvascular disease

Although this retrospective cohort study was limited by its observational design and the risk of confounding by indication, the results should help diabetes patients make informed decisions about their treatment options, the authors said.

Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM

A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.

Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes

The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.

New warnings for fluoroquinolones about risk of hypoglycemic coma

The labeling changes for fluoroquinolones will also make the mental health side effects more prominent and more consistent across the drug class.